PA-FOREST-DEVICES
23.2.2021 16:02:08 CET | Business Wire | Press release
Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE . LVOs are the type of ischemic stroke that require an interventional thrombectomy, only available at highly specialized hospitals, and every minute of treatment delay increases the risk of death and permanent disability.
The study showed that, compared to the clinical exams currently used by medics in the field to make triage decisions, AlphaStroke was 28% - 40% superior at correctly identifying patients with LVO, and equally good as the clinical exams, at correctly ruling out patients with non-LVO diagnoses.
“The results from the EDGAR study are a high-water mark in the global effort to improve early identification of patients needing thrombectomy,” said Matt Kesinger, CEO of FDI. “As a former EMT on ambulances, I experienced the challenge of correctly identifying stroke patients with only a few clinical exam questions. The EDGAR study is the first study, in which a portable technology, designed specifically for LVO identification, has been shown to outperform clinical exams currently applied by EMT’s worldwide.”
“The EDGAR study shows AlphaStroke™ has the potential to dramatically improve the detection of large vessel occlusion stroke in the prehospital environment,” said Dr. Paulina Sergot, lead author of the study and Emergency Medicine physician at Memorial Hermann hospital in Houston, Texas, one of the hospitals participating in the EDGAR study.
“This technology will be a game-changer in the prehospital,” said senior study author Dr. Frank Peacock, Vice Chair for Research of Emergency Medicine, Baylor College of Medicine. “Easy, fast, and more accurate than clinical impression for the diagnosis of LVO, using AlphaStroke™ on ambulances will mean more stroke victims getting to the right hospital as soon as possible. Time is brain, and fast treatment is the only thing that can prevent death or permanent disability from stroke.”
FDI’s diagnostic platform, AlphaStroke ™, is designed to support prehospital healthcare providers in identifying stroke.
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania and Calgary, Alberta that has developed AlphaStroke, the first prehospital stroke detection technology. The company strives to reduce functional disability from stroke by eliminating delays in stroke treatment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005078/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 14:01:00 CEST | Press release
Prelude Ventures led the round, with participation from JERA Co., Inc., Japan's largest power generation company, and Idemitsu Kosan, one of Japan's largest integrated energy companies Series B equity is the first component of a diverse financing that includes project-level capital and debt Quaise's millimeter wave drilling system is approaching one kilometer of depth at its Central Texas field site Series B proceeds fund Project Obsidian in Central Oregon, the world’s first commercial superhot geothermal power plant Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features mult
UMA Unveils Its Vision for the Next Generation of Humanoid Robots7.7.2026 14:00:00 CEST | Press release
At Machina Summit, UMA unveils the design of its first humanoid robot and introduces Real-Time Learning, a new AI architecture that enables robots to learn new skills through demonstration rather than programming. At Machina Summit, UMA, a Physical AI company, unveiled the design of its first humanoid robot and introduced Real-Time Learning, a learning architecture that enables robots to acquire new skills through demonstration instead of manual programming. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707215927/en/ The announcement comes as aging populations, industrial reshoring, and the energy transition place increasing pressure on labor markets across advanced economies. According to Korn Ferry, the global economy could face a shortage of 85 million workers by 2030, representing as much as $8.5 trillion in unrealized economic output. Against this backdrop, UMA is developing a new generation of intelligent robots bu
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 14:00:00 CEST | Press release
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W
Bregal Milestone III Closes at its Increased Hard Cap of €915 Million7.7.2026 13:00:00 CEST | Press release
Oversubscribed fundraise with global institutional backing Bregal Milestone (“Milestone” or the “Firm”), a leading European software private equity firm, today announced the final close of its third fund, Bregal Milestone III (“Fund III” or the “Fund”), at its increased hard cap of €915 million. The Fund was oversubscribed and marks a significant broadening of the Firm’s global investor base. Completed in eight months from first close and achieved against a challenging fundraising environment, the result reflects the strength of Milestone’s AI-centric approach and demonstrable track record. Jan Bruennler, Philippe Lautenberg and Cyrus Shey, Co-Founders and Managing Partners at Bregal Milestone, commented: “Bregal Milestone III reflects strong conviction in our approach to investing in mission-critical European software, AI and cybersecurity businesses and helping them scale. We are thankful for the support and confidence shown by our limited partners, both longstanding and new, and rem
HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics7.7.2026 12:39:00 CEST | Press release
HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707870943/en/ HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. The partnership comes as Embotech’s proven autonomous driving solutions are being adopted across a growing number of vehicle platforms
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom